Based on our phenotypic analysis of cDC2 subsets, we describe a CD163+CD206+CD11b+HLA-DRlow phenotype for CD1c+CD14+ DCs in NSCLC and HDs, aligning with the DC3 phenotype. This evidence concerns the gene CD1C and non-small cell lung carcinoma.